Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.